Tail vein administration of CD147 blocking antibody, following the dosing timeline depicted in Figure 4A, reduced protein expression of MMP-9 when measured 72 hours after stroke (IgG control 0.925±0.008 vs. CD147 antibody 0.723±0.04 relative to actin, p<0.01, n=4, Figure 4B and quantified Figure 4C). This evidence concerns the gene MMP9 and stroke disorder.